Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
2.2
%（既存のIsofol社出資比率）Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Capital and Business Alliance4597Solasia Pharma K.K.
Alliance partnerIsofol Medical AB
Details of the alliance
- 1
当社はIsofol社新株予約権2,083,332株相当分すべての行使を行う旨約定した。
- 2
他の新株予約権者の行使動向により新株予約権の未行使が生じた場合に、当社がIsofol社新株を最大で2,083,332株引き受けることを約定した。
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Capital and personnel relationships
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
2.20%Our ownership stake in the partner’s shares
Number of shares acquired新株予約権行使分2,083,332株相当、追加引受分最大2,083,332株。発行済株式総数に対する割合：Not disclosed
Shareholding Policy取得する株式には継続保有ロックアップ条項は付されず、一定の流動性は担保される。
About the partner
Business Description当社開発品SP-05の権利導入元／開発パートナー／グローバル権利者
LocationSweden
Share Acquisition Date and Payment Date新株予約権の行使期間は2026年3月16日から2026年3月30日。追加引受の実行日はNot disclosed。
| Item | Details |
|---|---|
| Name of alliance partner | Isofol Medical AB |
| Alliance partner's business activities | 当社開発品SP-05の権利導入元／開発パートナー／グローバル権利者 |
| Alliance partner's location | Sweden |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | 当社はIsofol社新株予約権2,083,332株相当分すべての行使を行う旨約定した。, 他の新株予約権者の行使動向により新株予約権の未行使が生じた場合に、当社がIsofol社新株を最大で2,083,332株引き受けることを約定した。 |
| Number of shares acquired | 新株予約権行使分2,083,332株相当、追加引受分最大2,083,332株。発行済株式総数に対する割合：Not disclosed |
| Shareholding ratio | 2.2% → Not disclosed |
| Shareholding Policy | 取得する株式には継続保有ロックアップ条項は付されず、一定の流動性は担保される。 |
| Share Acquisition Date and Payment Date | 新株予約権の行使期間は2026年3月16日から2026年3月30日。追加引受の実行日はNot disclosed。 |
Items this document does not state (14)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeAcquisition priceOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceDate of board resolutionContract DateAlliance start dateImpact on Business PerformanceChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.追加出資資金の一部をSP-05の臨床試験に拠出し、今後のIsofol社との連携をより深めるため。また、日本以外の地域でのSP-05開発進捗による経済価値の一部を享受することが期待されるため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.